Evaluation of Reference variability [Design Issues]

posted by Ohlbe – France, 2009-04-17 10:04  – Posting: # 3553
Views: 2,339

Dear Nirali,

» Shall it be appropriate design to evaluate reference variability for EU regulatory? :confused:

This was not the approach recommended at the EGA meeting last October. The preferred approach was to have a 3- or 4-period replicate study, with the reference administered twice, and the test once or twice. It seems that they are afraid that you might run a messy trial to show a high variability with the reference alone, and use these results to justify wider acceptance limits in a clean 2x2 trial with test and reference afterwards.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
20,346 posts in 4,274 threads, 1,404 registered users;
online 16 (0 registered, 16 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 09:40 CET

The belief that there is only one truth and
that oneself is in possession of it,
seems to me the deepest root of all
that is evil in the world.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5